Sarah Gregory1, Jeffrey D Long, Sarah J Tabrizi, Geraint Rees. 1. aHuntington's Disease Research Centre, UCL Institute of Neurology, London, UK bDepartments of Psychiatry and Biostatistics, University of Iowa, Iowa City, Iowa, USA cWellcome Trust Centre for Neuroimaging dInstitute of Cognitive Neuroscience, University College London, London, UK.
Abstract
PURPOSE OF REVIEW: Despite signs of cortical and subcortical loss, patients with prodromal and early-stage neurodegenerative disease are able to perform at a level comparable to the normal population. It is presumed that the onset of compensatory processes, that is changes in brain activation within a function-specific network or in the recruitment of a region outside of the task-network, underlies this maintenance of normal performance. However, in most studies to date, increased brain activity is not correlated with indices of both disease and performance and what appears to be compensation could simply be a symptom of neurodegeneration. RECENT FINDINGS: MRI studies have explored compensation in neurodegenerative disease, claiming that compensation is evident across a number of disorders, including Alzheimer's and Parkinson's disease, but generally always in early stages; after this point, compensation is generally no longer able to operate under the severe burden of disease. However, none of these studies explicitly adopted a particular model of compensation. Thus, we also discuss our recent attempts to operationalize compensation for empirical testing. SUMMARY: There is clear evidence of compensatory processes in the early stages of neurodegenerative disease. However, for a more complete understanding, this requires more explicit empirical modelling.
PURPOSE OF REVIEW: Despite signs of cortical and subcortical loss, patients with prodromal and early-stage neurodegenerative disease are able to perform at a level comparable to the normal population. It is presumed that the onset of compensatory processes, that is changes in brain activation within a function-specific network or in the recruitment of a region outside of the task-network, underlies this maintenance of normal performance. However, in most studies to date, increased brain activity is not correlated with indices of both disease and performance and what appears to be compensation could simply be a symptom of neurodegeneration. RECENT FINDINGS: MRI studies have explored compensation in neurodegenerative disease, claiming that compensation is evident across a number of disorders, including Alzheimer's and Parkinson's disease, but generally always in early stages; after this point, compensation is generally no longer able to operate under the severe burden of disease. However, none of these studies explicitly adopted a particular model of compensation. Thus, we also discuss our recent attempts to operationalize compensation for empirical testing. SUMMARY: There is clear evidence of compensatory processes in the early stages of neurodegenerative disease. However, for a more complete understanding, this requires more explicit empirical modelling.
Authors: Yifei Zhang; Lee Simon-Vermot; Miguel Á Araque Caballero; Benno Gesierich; Alexander N W Taylor; Marco Duering; Martin Dichgans; Michael Ewers Journal: Neurobiol Aging Date: 2016-05-03 Impact factor: 4.673
Authors: Kathrin Malejko; Patrick Weydt; Sigurd D Süßmuth; Georg Grön; Bernhard G Landwehrmeyer; Birgit Abler Journal: PLoS One Date: 2014-12-26 Impact factor: 3.240
Authors: Ming-Ching Wen; Hannah S E Heng; Samuel Y E Ng; Louis C S Tan; Ling Ling Chan; Eng King Tan Journal: Sci Rep Date: 2016-10-20 Impact factor: 4.379
Authors: Sarah Gregory; Jeffrey D Long; Stefan Klöppel; Adeel Razi; Elisa Scheller; Lora Minkova; Marina Papoutsi; James A Mills; Alexandra Durr; Blair R Leavitt; Raymund A C Roos; Julie C Stout; Rachael I Scahill; Douglas R Langbehn; Sarah J Tabrizi; Geraint Rees Journal: Brain Date: 2017-04-01 Impact factor: 13.501
Authors: Stefan Klöppel; Bogdan Draganski; Hartwig R Siebner; Sarah J Tabrizi; Cornelius Weiller; Richard S J Frackowiak Journal: Brain Date: 2009-04-15 Impact factor: 13.501
Authors: Laura J de Schipper; Anne Hafkemeijer; Jeroen van der Grond; Johan Marinus; Johanna M L Henselmans; Jacobus J van Hilten Journal: Front Neurol Date: 2018-06-06 Impact factor: 4.003
Authors: Renata Rozovsky; Amelia Versace; Lisa K Bonar; Michele Bertocci; Cecile D Ladouceur; Jay Fournier; Kelly Monk; Halimah Abdul-Waalee; Genna Bebko; Danella Hafeman; Dara Sakolsky; Tina Goldstein; Boris Birmaher; Mary L Phillips Journal: Neuropsychopharmacology Date: 2021-07-20 Impact factor: 7.853